Examination of the decline in symptoms of anxiety and depression in generalized anxiety disorder: Impact of anxiety sensitivity on response to pharmacotherapy

Depression and Anxiety

Volumn 25, Issue 2, 2008, Pages 167-171

  Olatunji, Bunmi O ^a   Feldman, Greg ^b,c   Smits, Jasper A J ^d   Christian, Kelly M ^c   Zalta, Alyson K ^c   Pollack, Mark H ^c   Simon, Naomi M ^c  

^a VANDERBILT UNIVERSITY   (United States)

^b SIMMONS COLLEGE   (United States)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

^d SOUTHERN METHODIST UNIVERSITY   (United States)

Author keywords

Anxiety; Anxiety sensitivity; Depression; Fluoxetine; Generalized anxiety disorder

Indexed keywords

FLUOXETINE;

ADULT; AGED; ANXIETY; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DISEASE ASSOCIATION; DRUG DOSE INCREASE; DRUG EFFECT; FEMALE; GENERALIZED ANXIETY DISORDER; HUMAN; MALE; PRIORITY JOURNAL; PSYCHOPHARMACOTHERAPY; TREATMENT RESPONSE;

ADOLESCENT; ADULT; AGED; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; ANXIETY DISORDERS; DEPRESSIVE DISORDER; FEMALE; FLUOXETINE; HUMANS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; PERSONALITY INVENTORY; SEROTONIN UPTAKE INHIBITORS; TREATMENT OUTCOME;

EID: 40349106455     PISSN: 10914269     EISSN: 15206394     Source Type: Journal    
DOI: 10.1002/da.20283     Document Type: Article

References (27)

1. American Psychiatric Association. 1994. Diagnostic and Statistical manual of mental disorders. 4th ed. Washington, DC: Author.
2. Bielski RJ, Bose A, Chang C-C. 2005. A double blind comparison of escitalopram and paroxetine in the long-term treatment of generalized anxiety disorder. Ann Clin Psychiatry 17:65-69.
3. Blazer DG, Hughes D, George LK, Swartz M, Boyer R. 1991. Generalized anxiety disorder. In: Robins LH, Regier DA, editors. Psychiatric disorders in America. New York: Free Press. p 180-203.
4. Breitholtz E, Westling BE, Ost L. 1998. Cognitions in generalized anxiety disorder and panic disorder patients. J Anxiety Disord 12: 567-577.
5. Bryk AS, Raudenbush SW, Congdon RT Jr. 1996. HLM: Hierarchical linear and nonlinear modeling with the HLM/2L and HLM/3L programs. Chicago, IL: Scientific Software International.
6. Cox BJ, Borger SC, Enns MW. 1999. Anxiety sensitivity and emotional disorders: Psychometric studies and their theoretical implications. In: Taylor S, editor. Anxiety sensitivity: Theory, research, and treatment of the fear of anxiety. Mahwah, NJ: Lawrence Erlbaum. p 115-148.
7. Cox BJ, Enns MW, Freeman P, Walker JR. 2001. Anxiety sensitivity and major depression: Examination of affective state dependence. Behav Res Ther 39:1349-1356.
8. Gould RA, Otto MW, Pollack MH, Yap L. 1997. Cognitive behavioral and pharmacological treatment of generalized anxiety disorder: A preliminary meta-analysis. Behav Ther 28:285-305.
9. Hamilton M. 1959. The assessment of anxiety states by rating. Br J Med Psychol 32:50-55.
10. Hamilton M. 1960. A rating scale for depression. J Neurol Neurosurg Psychiatry 23:56-62.
11. Joormann J, Kosfelder J, Schulte D. 2005. The impact of comorbidity of depression on the course of anxiety treatments. Cogn Ther Res 29:569-591.
12. Mennin DS, Heimberg RG, Turk C, Fresco D. 2005. Preliminary evidence for an emotion dysregulation model of generalized anxiety disorder. Behav Res Ther 43:1281-1310.
13. Moscovitch D, Hofmann S, Suvak M, In-Albon T. 2005. Mediation of changes in anxiety and depression during treatment of social phobia. J Consult Clin Psychol 73:945-952.
14. Noyes R. 2001. Comorbidity in generalized anxiety disorder. Psychiatr Clin North Am 24:41-55.
15. Otto MW, Pollack MH, Fava M, Uccello B, Rosenbaum J. 1995. Elevated Anxiety Sensitivity Index scores in patients with major depression: Correlates and changes with antidepressant treatment. J Anxiety Disord 9:117-123.
16. Pollack MH, Simon NM, Zalta AK, Worthington JW, Hoge E, Kinrys G, Oppenheimer J. 2006. Olanzapine augmentation of fluoxetine for refractory generalized anxiety disorder: A placebo controlled study. Biol Psychiatry 59:211-215.
17. Raudenbush SW, Bryk AS. 2002. Hierarchical linear models: Applications and data analysis methods. Thousand Oaks, CA: Sage.
18. Reiss S. 1991. The expectancy model of fear, anxiety, and panic. Clin Psychol Rev 11:141-153.
19. Reiss S, McNally RJ. 1985. The expectancy model of fear. In: Reiss S, Bootzin R, editors. Theoretical issues in behavior therapy. New York: Academic Press. p 107-121.
20. Reiss S, Peterson RA, Gursky DM, McNally RJ. 1986. Anxiety sensitivity, anxiety frequency and the prediction of fearfulness. Behav Res Ther 24:1-8.
21. Rosenbaum JF, Pollack MH, Pollack RA. 1996. Clinical issues in the long-term treatment of panic disorder. J Clin Psychiatry 57:44-48.
22. Silverstone PH, Salinas E. 2001. Efficacy of venlafaxine extended release in patients with major depressive disorder and comorbid generalized anxiety disorder. J Clin Psychiatry 62:523-529.
23. Simon NM, Otto MW, Smits J, Nicolaou DC, Reese H, Pollack MH. 2004. Changes in anxiety sensitivity with pharmacotherapy for panic disorder. J Psychiatr Res 38:491-495.
24. Stein DJ, Andersen HF, Goodman WK. 2005. Escitalopram for the treatment of GAD: Efficacy across different subgroups and outcomes. Ann Clin Psychiatry 17:71-75.
25. Wittchen HU, Zhao S, Kessler RC, Eaton WW. 1994. DSM-III-R generalized anxiety disorder in the National Comorbidity Survey. Arch Gen Psychiatry 51:355-364.
26. Zinbarg RE, Barlow DH, Brown TA. 1997. Hierarchical structure and general factor saturation of the anxiety sensitivity index: Evidence and implications. Psychol Assess 9:277-284.
27. Zinbarg RE, Brown TA, Barlow DH, Rapee RM. 2001. Anxiety sensitivity, panic, and depressed mood: A reanalysis teasing apart the contributions of the two levels in the hierarchical structure of the anxiety sensitivity index. J Abnorm Psychol 110:372-377.